Nuvation Bio Inc. Increase (Decrease) in Inventories and Other Operating Assets
Nuvation Bio Inc. (NUVB) reported Increase (Decrease) in Inventories and Other Operating Assets of $8.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventoriesAndOtherOperatingAssets · last filed 2026-08-06
- Nuvation Bio Inc. increase (decrease) in inventories and other operating assets for the quarter ending 2026-06-30 was $4.06M, a 654.09% increase year-over-year.
- Nuvation Bio Inc. increase (decrease) in inventories and other operating assets for the quarter ending 2026-03-31 was $4.43M, a 31564.29% increase year-over-year.
- Nuvation Bio Inc. increase (decrease) in inventories and other operating assets for the quarter ending 2025-12-31 was $5.70M.
- Nuvation Bio Inc. increase (decrease) in inventories and other operating assets for the quarter ending 2025-09-30 was $5.16M.
- Nuvation Bio Inc. increase (decrease) in inventories and other operating assets for fiscal 2025 was $11.41M.
- Nuvation Bio Inc. increase (decrease) in inventories and other operating assets for fiscal 2024 was $0.00.
| Period end | Increase (Decrease) in Inventories and Other Operating Assets 3 month | Increase (Decrease) in Inventories and Other Operating Assets 6 month | Increase (Decrease) in Inventories and Other Operating Assets 9 month | Increase (Decrease) in Inventories and Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $8.49M 10-Q · filed 2026-08-06 | $14.19M derived: sum of 3 quarters · filed 2026-08-06 | $19.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.43M 10-Q · filed 2026-05-04 | $10.13M derived: sum of 2 quarters · filed 2026-05-04 | $15.29M derived: sum of 3 quarters · filed 2026-05-04 | $15.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $10.86M derived: sum of 2 quarters · filed 2026-03-02 | $11.40M derived: sum of 3 quarters · filed 2026-08-06 | $11.41M 10-K · filed 2026-03-02 |
| 2025-09-30 | $5.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $5.70M derived: sum of 2 quarters · filed 2026-08-06 | $5.71M 10-Q · filed 2025-11-03 | $5.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $538.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $552.00K 10-Q · filed 2026-08-06 | $552.00K derived: sum of 3 quarters · filed 2026-08-06 | $552.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $14.00K 10-Q · filed 2026-05-04 | $14.00K derived: sum of 2 quarters · filed 2026-05-04 | $14.00K derived: sum of 3 quarters · filed 2026-05-04 | $14.00K derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $0.00 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |